Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk wins approval for its weight-loss drug from China
Novo Nordisk A/S (CPH: NOVO-B) climbed 3.0% to an all-time high on Tuesday after China approved the sale of its weight-loss treatment Wegovy. Year-to-date, shares of the pharmaceutical giant are now up a whopping 45%.
Wegovy Approved In China—But Novo Nordisk Promises Existing Patients Priority Amid Shortages
Ozempic maker Novo Nordisk confirmed Tuesday its popular weight loss drug Wegovy had been approved for sale in China, a key victory for the Danish firm that opens the door to an enormous market, but the company told Forbes it will only launch there once it could guarantee supplies for those already taking it as shortages plague the U.S. market and elsewhere.
Novo Nordisk's Wegovy weight loss drug approved in China
Novo Nordisk said Tuesday that its Wegovy weight loss treatment has been approved in China for long-term weight management. The approval opens up the blockbuster drug for sale for those with obesity and at least one weight-related comorbidity.
Ozempic maker Novo Nordisk to spend $4.1bn on North Carolina facility
Novo Nordisk (NYSE:NVO) is investing $4.1 billion to expand its US manufacturing, focusing on its high-demand weight-loss drugs, Ozempic and Wygovy. The investment will fund a new 1.4 million square foot plant near Raleigh, North Carolina, doubling the site's size.
Novo Nordisk says Semaglutide approved for long-term weight management in China
Novo Nordisk's drug Semaglutide has been approved in China for long-term weight management, the company said in a post on an official WeChat account on Tuesday.
Novo Nordisk Invests $4.1 Billion For New US Facility—Boosting Ozempic Production
Novo Nordisk will invest $4.1 billion to develop a new manufacturing facility in the U.S., which will be used to boost production for the company's weight loss and diabetes drugs Wegovy and Ozempic, the Danish firm said Monday.
Wegovy-maker Novo Nordisk to spend $4.1 bln to boost US manufacturing
Obesity drug-maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and diabetes drug Ozempic, it said on Monday.
Novo Nordisk to build $4.1 billion North Carolina facility to boost output of Wegovy, Ozempic
Novo Nordisk said it will spend $4.1 billion to boost the supply of its blockbuster weight loss drug Wegovy, diabetes treatment Ozempic and other injectable therapies. The investment will fund a new manufacturing plant in Clayton, North Carolina, responsible for filling and packaging syringes and injection pens for the drugs.
Teva launches generic version of Novo Nordisk's diabetes drug Victoza
Teva Pharmaceuticals said on Monday it has launched the generic version of Danish drugmaker Novo Nordisk's drug Victoza to treat patients with type 2 diabetes.
Nestle launches 'Ozempic face' range as sales of weight-loss drugs soar
Swiss consumer products giant Nestle S.A. (OTC:NSRGF, VTX:NESN)is introducing to help disguise the effect of rapid weight loss brought by the use of drugs such as Novo Nordisk (NYSE:NVO)'s Ozempic and Wegovy and Eli Lily's Mounjaro Nestle is bracing itself for a slump in sales of staples such as KitKat and Smarties due to the demand for weight-loss products, but is not sitting still with the new product lines to counteract the effect known as ‘Ozepmic face”.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo's Wegovy induces higher weight loss in women than men with same heart condition, study shows
Novo Nordisk's popular obesity drug Wegovy helped women with a common heart disease lose more weight than men who had the same condition, an analysis of study data published in a medical journal has shown.
